Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
64 participants
INTERVENTIONAL
2002-09-30
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
NCT00044889
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00337168
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
NCT01960387
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
NCT00042354
Clofarabine in Chronic Lymphocytic Leukemia
NCT00028418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Completion date provided represents the completion date of the grant per OOPD records
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clofarabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate cardiac status
* No life-threatening conditions (e.g. infections) which may cause death within 3 weeks.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hagop M Kantarjian, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Jorge E Cortes, MD
Role: STUDY_CHAIR
M.D. Anderson Cancer Center
References
Explore related publications, articles, or registry entries linked to this study.
Cortes JE, Gandhi V, et al. Clofarabine (2-chloro-9-(deoxy-2-fluoro-b-D-arabinosfuranosyl)adenine) is active for patients with refractory or relapsed acute leukemia. #739 ASH 2002.
Related Links
Access external resources that provide additional context or updates about the study.
FDA's clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.